This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
DUBLIN, Calif., April 3, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of thirteen abstracts covering internal and partner funded pipeline product data for poster or oral presentation at the American Association for Cancer Research (AACR) Annual Meeting April 6 to 10, 2013 in Washington, DC.
"AACR will be a foundational meeting for presenting significant data supporting our clinical programs," said James S.J. Manuso, PhD, chairman and chief executive officer. "Additional data presentations are anticipated for future meetings. Preliminary SGI-110 phase 2 data are expected to be presented at ASH."
SGI-110, a novel hypomethylating agent, will be highlighted in six presentations, including an oral mini-symposia presentation on ovarian cancer chemosensitization, as well as poster presentations on its immunomodulatory activity and its activity in lung cancer:
In vivo Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent, in Hematologic Malignancies
CDK4/CDK6 Inhibition is Potently Active in a Definable Subset of Human Neuroblastomas
Abstract 2744, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation
Additional poster references may be found on the AACR 2013 Annual Meeting website, and select posters will be made available for viewing on the company's website
www.astx.com following the respective presentations.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.